Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study-Reference-Cited by-同舟云学术

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

Published:2021-07-23 Issue: Volume: Page:
ISSN:1598-9100
Container-title:Intestinal Research
language:en
Short-container-title:Intest Res

Author:

Shin Seung Yong^ORCID,Park Soo Jung^ORCID,Kim Young^ORCID,Im Jong Pil^ORCID,Kim Hyo Jong^ORCID,Lee Kang-Moon^ORCID,Kim Ji Won^ORCID,Jung Sung-Ae^ORCID,Lee Jun^ORCID,Kang Sang-Bum^ORCID,Shin Sung Jae^ORCID,Kim Eun Sun^ORCID,Kim You Sun^ORCID,Kim Tae Oh^ORCID,Kim Hyun-Soo^ORCID,Park Dong Il^ORCID,Kim Hyung Kil^ORCID,Kim Eun Soo^ORCID,Kim Young-Ho^ORCID,Kim Do Hyun^ORCID,Teng Dennis^ORCID,Kim Jong-Hwa^ORCID,Kim Wonyong^ORCID,Choi Chang Hwan^ORCID,

Publisher

Korean Association for the Study of Intestinal Diseases

Subject

Gastroenterology

Link

http://irjournal.org/upload/pdf/ir-2021-00049.pdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets;Gut Pathogens;2024-08-26

3. Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis;Health Science Reports;2024-07

4. Dynamic Changes in the Gut Microbiota Composition during Adalimumab Therapy in Patients with Ulcerative Colitis: Implications for Treatment Response Prediction and Therapeutic Targets;2024-02-19

5. Predictive, preventive and personalised approach as a conceptual and technological innovation in primary and secondary care of inflammatory bowel disease benefiting affected individuals and populations;EPMA Journal;2024-02-09